Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 inches tall, and weighs 270 pounds. He is treating ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

More than 1000 people -- shoulder-to-shoulder in bleachers, on the ground and on folding chairs -- jammed the Clackamas ...

Briana Adesso, 31, was a very social person who would routinely go out with friends when she suddenly gained about 40 pounds ...

Infowars host Alex Jones has finally addressed long standing rumors that he used Ozempic to lose weight. Speculation has run ...

A fast-growing body of research signals potential health benefits ... An analysis of a large trial involving adults with ...